Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.34 |
| ▸ | SYK | P43405 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13860322 | 0.91 | JAK3 (0.36) | DGAT1JAK3 | |
| SCHEMBL13858311 | 0.88 | JAK3 (0.34) | DGAT1JAK3 | |
| SCHEMBL2344746 | 0.84 | JAK3 (0.36) | DGAT1JAK3 | |
| SCHEMBL13860408 | 0.84 | JAK3 (0.34) | DGAT1SYKJAK3 | |
| SCHEMBL13858191 | 0.81 | JAK3 (0.37) | DGAT1JAK3KLKB1 | |
| SCHEMBL13858240 | 0.81 | JAK3 (0.41) | JAK3 | |
| SCHEMBL13858099 | 0.81 | SYK (0.42) | DGAT1SYKJAK3 | |
| SCHEMBL13858301 | 0.80 | JAK3 (0.51) | JAK3 | |
| SCHEMBL13858289 | 0.80 | JAK3 (0.51) | JAK3 | |
| SCHEMBL13858118 | 0.80 | JAK3 (0.40) | DGAT1SYKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187487-B2 | Azaindole derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2710006-A1 | AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20140073626-A1 | AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Principia Biopharma (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2012158785-A1 | AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073626-A1 | AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | BMX, BLK, ITK | DGAT1 3759/4885SYK 43/4885MAPT 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.